The Efficacy, Safety & Modification of Albuminuria in type 2 Diabetes Subjects with Renal Disease with LINAgliptin (MARLINA-T2D; NCT 01792518) was a randomized clinical trial evaluating (and showing) the glycemic efficacy of the dipeptidyl peptidase-4 inhibitor, linagliptin (5 mg daily for 24 weeks), on top of recommended standard care for diabetic kidney disease [42]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.